Empagliflozin initiated within 14 days after acute myocardial infarction reduced first hospitalization for heart failure by 23% compared to placebo (HR 0.77; 95% CI 0.60–0.98; p=0.031) in post-MI patients.
Patients with Type 2 Myocardial Infarction (T2MI)
Diagnostic pathways and therapeutic strategies (invasive vs conservative, including drug-coated balloon angioplasty and stentless PCI)
This review highlights the need for individualized diagnostic and therapeutic approaches, including conservative and alternative revascularization strategies, for patients with Type 2 Myocardial Infarction.
Effect estimate: HR 0.77 (95% CI 0.60–0.98)
p-value: p=0.031
Type 2 myocardial infarction (T2MI) is defined as myocardial necrosis caused by an imbalance between oxygen supply and demand in the absence of acute atherothrombotic coronary occlusion/erosion. Unlike type 1 myocardial infarction (T1MI), T2MI comprises a heterogeneous group of clinical scenarios, often triggered by systemic or cardiac conditions, and it frequently affects elderly patients with a high burden of comorbidities. T2MI often underline multivessel coronary artery disease and, despite its growing clinical relevance, the diagnostic and therapeutic approach to T2MI remains challenging and lacks standardized recommendations. In this review, we present an updated and a comprehensive synthesis of current evidence on the diagnosis and management of T2MI, focusing on the role of coronary angiography and interventional strategies. We discuss the utility of high-sensitivity cardiac biomarkers, imaging modalities, and clinical risk scores to guide patient selection for invasive evaluation. Specific attention is given to conservative and alternative revascularization approaches—including drug-coated balloon angioplasty and stentless percutaneous coronary intervention (PCI)—in frail and high-bleeding-risk patients. The review emphasizes the need for individualized decision-making in a population where standard invasive strategies may not always be appropriate, and where a tailored balance between ischemic and hemorrhagic risk is crucial.
Building similarity graph...
Analyzing shared references across papers
Loading...
Sebastian Cinconze
Comelz (Italy)
Chiara Bernelli
Ospedale Santa Corona
F Giordana
Azienda Sanitaria Ospedaliera S.Croce e Carle Cuneo
Journal of Clinical Medicine
Azienda Sanitaria Ospedaliera S.Croce e Carle Cuneo
Ospedale Santa Corona
Comelz (Italy)
Building similarity graph...
Analyzing shared references across papers
Loading...
Cinconze et al. (Thu,) conducted a review in Elderly and comorbid patients with type 2 myocardial infarction often complicated by multivessel coronary artery disease and high bleeding risk. Empagliflozin vs. Placebo was evaluated on First hospitalization for heart failure (HR 0.77, 95% CI 0.60–0.98, p=0.031). Empagliflozin initiated within 14 days after acute myocardial infarction reduced first hospitalization for heart failure by 23% compared to placebo (HR 0.77; 95% CI 0.60–0.98; p=0.031) in post-MI patients.
synapsesocial.com/papers/698828410fc35cd7a88479ac — DOI: https://doi.org/10.3390/jcm15031279